NCT02202408View on ClinicalTrials.gov

Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of SKI2670

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

June 30, 2014

Primary Completion Date

August 31, 2016

Study Completion Date

August 31, 2016

Conditions
Endometriosis
Interventions
DRUG

SKI2670

Oral, Single Dose

DRUG

Placebo

Same shape as the experimental drug

Trial Locations (1)

138-736

Asan Medical Center, Seoul

All Listed Sponsors
lead

SK Chemicals Co., Ltd.

INDUSTRY

NCT02202408 - Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of SKI2670 | Biotech Hunter | Biotech Hunter